Company Information
Ambys Medicines was founded on January 2018. The company is based in Redwood City, CA, USA . The number of employees in Ambys Medicines is less than 50. Ambys medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.Here is how Ambys Medicines describes itself: "With our cell and gene therapies, we are developing medicines to directly impact the complex biology driving severe liver diseases."
Funding & investors
Ambys Medicines has received 2 rounds of venture funding. The total funding amount is around $140M.- Takeda Ventures (Corporate venture capital)
- Third Rock Ventures (Venture capital)
Similar Companies [beta]
- Singlera genomics
- Fusion genomics corporation
- Bactana animal health
- Athletigen
- Aileron therapeutics
- Aduro
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
- Active Investors in Wellness
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
- Best Funded Wellness Startups
News
Ambys Medicines - Blog
- Ambys Medicines Appoints Dr. Corinne Foo-Atkins as Chief Strategy Officer
- Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform
- Ambys Medicines Announces Appointment of Founder Markus Grompe, M.D., as Chief Scientific Officer
- Ambys Medicines announces John Choi is joining as VP of Regulatory Affairs as it initiates IND activities for its lead allogeneic liver cell transplantation program
- Ambys Medicines Announces Presentation on Novel Liver Cell Therapy Platform for Severe Liver Diseases, and Opening of its cGMP Cell Therapy Manufacturing Facility
- Ambys Medicines Appoints Ronald Park, M.D., Chief Executive Officer
SOUTH SAN FRANCISCO, Calif., January 20, 2022– Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, today announced the appointment of Corinne Foo-Atkins, MBBS, MBA, MSc, as the company’s first Chief Strategy Officer. Dr. Foo-Atkins will be responsible for providing cross-functional leadership for Ambys’s lead program, AMI-918—an allogeneic liver-cell therapy in development for … Read more
Financing led by Third Rock Ventures with participation from Takeda, Schroders Capital, Laurion Capital, Smilegate Investment, and Alexandria Venture Investments, among others Funding will enable completion of pre-IND activities in support of Ambys’s lead investigational therapy for severe liver disease Ambys is targeting initiation of a Phase 1/2 trial for its lead program, AMI-918, in … Read more
SOUTH SAN FRANCISCO, Calif., December 6, 2021– Ambys Medicines, a company aiming to be the leader in cell therapy for severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced the appointment of Markus Grompe, M.D., as the company’s Chief Scientific Officer. Dr. Grompe is a world-leading expert on stem cell research … Read more
South San Francisco, CA; October 13, 2021 – Ambys Medicines, a cell and gene therapy company focused on transforming the treatment of severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced that John Choi, MS, RAC, has joined as Vice President, Regulatory Affairs. John joins as Ambys prepares its IND for … Read more
Data presented at IXA-CTRMS-2021 demonstrate Ambys’ first-of-its-kind bioreactor manufacturing platform enables unprecedented large-scale expansion of high quality primary human hepatocytes 52,000 square foot cGMP manufacturing facility will support the industrialization and clinical scale-up of Ambys’s novel bioreactor platform to produce mature, fully functional human hepatocytes Ambys’ technology aims to deliver fully mature hepatocytes to treat … Read more
South San Francisco, CA; June 1, 2021 — Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Ronald Park, M.D., as the company’s new Chief Executive Officer. Dr. Park also joins the Ambys board of directors. Dr. Park is a … Read more
Share:
